Mitsubishi UFJ Asset Management Co. Ltd. Buys 11,777 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Mitsubishi UFJ Asset Management Co. Ltd. increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 3.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 318,820 shares of the medical equipment provider’s stock after purchasing an additional 11,777 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.16% of Zimmer Biomet worth $33,307,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of ZBH. Dunhill Financial LLC raised its position in shares of Zimmer Biomet by 1,090.0% during the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares during the last quarter. Stonebridge Financial Group LLC bought a new stake in Zimmer Biomet during the 4th quarter worth about $25,000. Brooklyn Investment Group bought a new stake in Zimmer Biomet during the 3rd quarter worth about $35,000. Kentucky Trust Co bought a new position in shares of Zimmer Biomet in the 4th quarter valued at about $39,000. Finally, OFI Invest Asset Management acquired a new stake in shares of Zimmer Biomet during the 4th quarter worth approximately $40,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Royal Bank of Canada decreased their price objective on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Barclays decreased their target price on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Finally, Raymond James cut their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $124.15.

Zimmer Biomet Price Performance

Shares of ZBH opened at $112.21 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a twelve month low of $97.69 and a twelve month high of $131.61. The stock has a market capitalization of $22.34 billion, a P/E ratio of 25.22, a P/E/G ratio of 1.95 and a beta of 1.04. The company has a 50 day moving average of $107.18 and a 200-day moving average of $107.02.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period in the prior year, the company earned $2.20 earnings per share. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.86%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the completion of the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 0.95% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.